Search

A recent study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, explored the effects of extracranial injections of Botulinum Toxin Type A on the activation and sensitization of central trigeminovascular neurons. The research focused on the mechanism of action of onabotA in preventing activation and sensitization of dura-sensitive neurons in the spinal trigeminal nucleus. The study found that onabotA was able to prevent activation and sensitization of wide-dynamic range neurons, but had no effect on high-threshold neurons. These findings provide pre-clinical evidence on the potential mechanisms of action of onabotA and other drugs targeting calcitonin gene-related peptide signaling. [Extracted from the article]

A researcher from Tehran University of Medical Sciences has detailed findings on the use of Botulinum Toxin A (BT-A) in treating migraine and non-migraine head pain. BT-A, known for its ability to inhibit acetylcholine release, has shown effectiveness in pain control by inhibiting neurotransmitters associated with pain and inflammation. Studies have demonstrated the beneficial effects of BT-A in treating primary and secondary headache disorders, suggesting its potential for chronic migraine prophylaxis and other headache conditions. [Extracted from the article]

Researchers from the Medical University of Warsaw have published new data on trigeminal neuralgia, a common form of craniofacial pain. The study highlights the efficacy of botulinum toxin type A therapy in alleviating pain for patients with trigeminal neuralgia, offering a potential alternative treatment option. The research provides an overview of trigeminal neuralgia, including its characteristics, etiology, epidemiology, classification, and management, with a focus on the use of botulinum neurotoxin A. [Extracted from the article]

A recent study conducted at the University Children's Hospital has explored the use of botulinum toxin (BoNT) in the treatment of gastrointestinal disorders in children. The researchers found that BoNT can be considered for children with achalasia, cricopharyngeal achalasia, delayed gastric emptying, anal achalasia, constipation after Hirschsprung disease corrective surgery, resistant functional constipation, and chronic anal fissure. The study suggests that BoNT may be a viable option for improving surgical outcomes and treating these conditions in selected pediatric patients. Further information on this research can be found in the Journal of Pediatric Gastroenterology and Nutrition. [Extracted from the article]

A recent study conducted at Stellenbosch University in South Africa examined the association between antipsychotic medication use and chronic dystonia, a condition characterized by sustained muscle contractions and abnormal postures. The study found that patients with antipsychotic-induced dystonia tended to present at a younger age, were more likely to be female, required higher doses of Botulinum toxin treatment, and incurred higher treatment costs compared to those with primary dystonia. The research also identified age and Botulinum toxin dose as factors associated with psychotropic-related dystonia. The study provides valuable insights into the demographic and clinical profiles of individuals with dystonia caused by antipsychotic medication, which can inform preventative strategies and improve patient care. [Extracted from the article]

A recent study conducted by Yonsei University College of Dentistry in Seoul, South Korea, examined the immunogenicity of botulinum toxin type A in different clinical and cosmetic treatments. The study found that while the overall incidence of neutralizing antibody formation with botulinum toxin type A treatment is relatively low, it varies depending on the indication and is influenced by factors such as the frequency of injections and the cumulative dose. The research highlights the need for further investigation into antibody formation mechanisms and the development of strategies to minimize their impact on treatment efficacy. For more information, the full article can be accessed through the provided link. [Extracted from the article]

This patent application discusses the development of pharmaceutical compositions containing Clostridial toxins, specifically botulinum toxin, for medical applications. The inventors propose a composition that includes a Clostridial toxin active ingredient, along with various excipients such as trehalose, poloxamer 188, polysorbate 20, L-methionine, N-acetyl-cysteine (NAC), and EDTA. These compositions are stable and suitable for injection, and the patent application also includes methods for making them and their potential use in treating depression and cardiac arrhythmia. The application aims to address the challenges associated with formulating and handling Clostridial toxin pharmaceutical compositions. [Extracted from the article]

A researcher from Tanta University in Egypt has conducted a study on the use of botulinum toxin therapy to manage salivary gland dysfunction caused by radiotherapy. The study involved injecting botulinum toxin into the salivary glands of rats before exposing them to radiation. The results showed that the botulinum-injected glands had better acinar architecture compared to the saline group, indicating that botulinum neurotoxin protected the salivary gland cells from the effects of radiation. This research suggests that botulinum toxin therapy could be an effective treatment for radiotherapy-induced salivary gland dysfunction. [Extracted from the article]

A recent study conducted by researchers from the Buddhist Tzu Chi Medical Foundation and Tzu Chi University in Hualien, Taiwan, explored the use of botulinum toxin A (BoNT-A) injections in the treatment of dysfunctional voiding (DV) in women. DV refers to abnormal urethral sphincter activity during voiding in individuals without neurological conditions. The study found that urethral sphincter denervation or reinnervation activity was commonly observed in women with DV. BoNT-A injections into the urethral sphincter provided effective treatment in nearly half of the patients, with mild improvement in urinary flow rate observed in those with reinnervation. However, the improvement was not superior to those without reinnervation. This research sheds light on the potential benefits and limitations of BoNT-A therapy for DV in women. [Extracted from the article]

A new study from Saint-Chamond, France, examines the use of botulinum toxin therapy in the treatment of acquired deforming hypertonia (ADH) in older patients. The study found that botulinum toxin injections (BTxis) were effective in providing comfort for older patients with ADH, although no functional goals were achieved. The study included 41 patients over the age of 70, most of whom lived in institutions and had significant morbi-mortality. The research suggests that BTxis have the potential to meet the needs of a larger number of older patients with ADH. [Extracted from the article]

Researchers at China Three Gorges University have conducted a study on the transdermal delivery of botulinum toxin-A (BTXA) through phosphatidylcholine/cholesterol (PC/Chol) nanoliposomes for the treatment of post-acne scarring (PSA). The study found that the BTXA@liposome nanoparticles had a greater diffusion depth compared to pure BTXA, reaching 380 μm. However, the BTXA@liposome/HA hydrogel treatment did not show significant advantages over hyaluronic acid (HA) hydrogel treatment in relieving PSA. Further research is needed to verify the feasibility and effectiveness of this method in PSA treatment. [Extracted from the article]

A recent study conducted at the Swiss Federal Institute of Technology Zurich (ETH) explored the feasibility of using a robotic hand orthosis as an adjunct therapy after botulinum toxin injections in individuals with upper-limb spasticity. The study involved five participants who received botulinum toxin injections and then engaged in a simulated unsupervised therapy session with the robotic hand orthosis. The results showed a reduction in muscle tone and functional improvements in the participants. The researchers concluded that the addition of the robotic hand orthosis therapy was safe and had the potential to enhance therapy doses and long-term outcomes. [Extracted from the article]

A patent application has been filed for a new method of treating headaches, specifically migraines, using neurotoxins. The current FDA-approved treatment, BOTOX, can have side effects such as muscle weakness and involves multiple injections. The new method aims to simplify the injection process and reduce side effects by targeting specific nerve pathways involved in migraines. The patent application outlines various injection sites and combinations that can be used to enhance the treatment's effectiveness. By avoiding certain areas, the occurrence and severity of side effects can be reduced. The inventors claim that their methods can provide more effective and targeted treatment for migraines and headaches. [Extracted from the article]

A recent study conducted at Rio Hortega University Hospital in Valladolid, Spain, explored the use of botulinum toxin type A (BoNT-A) for treating post-stroke spasticity (PSS). The researchers used natural language processing and machine learning to analyze data extracted from electronic health records (EHRs) of patients in five Spanish hospitals. The study found that 25.5% of patients with PSS received BoNT-A, primarily for pain relief, about one year after their stroke. The researchers emphasized the importance of early treatment, disease monitoring, and better documentation in EHRs to improve care for PSS patients. [Extracted from the article]

A study conducted in Hangzhou, China, examined the clinical effectiveness and safety of type A botulinum toxin in treating refractory overactive bladder in adolescents. The study involved 37 patients who received intravesical injections of the toxin and recorded changes in urination diaries and urodynamic parameters. After one month of treatment, significant improvements were observed in various urinary parameters. Mild side effects were reported in some patients, but no serious complications or adverse reactions were observed. The study concluded that type A botulinum toxin can be safely and effectively administered to adolescents with refractory overactive bladder, improving their symptoms and quality of life. [Extracted from the article]

A recent report from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida discusses the use of botulinum toxin therapy for the management of first bite syndrome, a condition that causes severe pain when salivating or taking the initial bites of a meal. Traditionally, pharmacological options such as anticonvulsants or tricyclic antidepressants have been used, but botulinum toxin injections have been found to be an effective alternative. The report presents a case of a patient with squamous cell carcinoma who experienced first bite syndrome and responded well to botulinum toxin injections. The research highlights the various treatment options available for this rare syndrome, including botulinum toxin. [Extracted from the article]

A study conducted at the University of Piemonte Orientale in Novara, Italy, examined the long-term effects of botulinum toxin type A (BoNT-A) treatment combined with rehabilitation on post-stroke spasticity. The study found that BoNT-A treatment resulted in a reduction in spasticity in all patients, but there was a time-dependent decline in improvement in gait parameters over repeated cycles. The researchers concluded that monitoring and treatment protocols are crucial for maintaining functional stability and preventing excessive fluctuations. These findings provide valuable prognostic indications for integrating different rehabilitation approaches after BoNT-A treatment. [Extracted from the article]

A recent study conducted by researchers at the University of California explores the use of botulinum toxin therapy in the treatment of secondary dystonia. Secondary dystonia is often associated with lesions in the putamen or globus pallidus and is commonly seen in neurodegenerative or neurometabolic conditions. The study included 14 patients with confirmed neurometabolic causes of dystonia, such as Wilson's disease and Niemann-Pick disease type C. The results showed that most patients experienced mild to moderate improvement in their dystonia symptoms with botulinum toxin therapy, lasting for approximately 6 to 12 weeks. The study concludes that chemo-denervation with botulinum toxin plays an important role in alleviating symptoms of secondary dystonia. [Extracted from the article]

A recent study conducted at the University of Campinas in Brazil explored the effects of low doses of botulinum toxin type A (BoNT-A) in controlling chronic pain in patients with temporomandibular disorder (TMD), sleep bruxism (SB), and awake bruxism (AB). The study included forty patients who received a single dose of BoNT-A in their masseter and temporalis muscles. The results showed a significant decrease in pain after 15 days of treatment for patients with all three conditions. However, the pain reduction in TMD was short-lived, suggesting that BoNT-A may be more effective for controlling pain in SB and AB. The researchers concluded that BoNT-A should be considered as an adjunctive and optional therapeutic strategy for pain control rather than a primary treatment. [Extracted from the article]

A recent study conducted by researchers at the Federal Budget Institution of Science in Moscow Region, Russia, focuses on botulinum toxin therapy. Botulism, a severe food intoxication, is caused by consuming poor quality canned or smoked foods. Monoclonal antibodies (mAbs) show promise in treating botulinum toxin type A intoxications due to their targeting action and lack of allergic reactions. The researchers obtained 14 murine mAbs and found that a cocktail of three antibodies effectively neutralizes the toxin. This cocktail could potentially be developed into a therapeutic drug for patients. [Extracted from the article]

Researchers at Hubei University of Medicine in Xiangyang, China have conducted a study on the potential use of Botulinum toxin A (BONT/A) in treating osteoarthritis (OA). The study found that BONT/A can inhibit the degeneration of chondrocytes, the cells responsible for cartilage production, through a process called ferroptosis. This discovery suggests that BONT/A may be a promising therapeutic option for OA. The research was funded by various organizations and has been peer-reviewed. [Extracted from the article]

A recent study conducted by researchers at the Second Affiliated Hospital of Soochow University in Suzhou, China, explored a novel approach to treating post-stroke depression (PSD) using Botulinum Toxin A (BoNT-A) administered through local facial injection. The study involved 71 stroke patients and compared the efficacy and side effects of BoNT-A treatment with traditional antidepressant medication. The results showed that BoNT-A therapy effectively reduced depression symptoms in patients with PSD, with fewer side effects compared to the antidepressant medication. This research provides valuable insights into potential alternative treatments for PSD. [Extracted from the article]

A recent study from Aldo Moro University in Bari, Italy, has explored the effectiveness of combining botulinum toxin type A and therapeutic exercise in treating spasticity in a patient with complicated Stiff-Person Syndrome (SPS). SPS is a rare autoimmune condition that primarily affects women, with no racial predisposition. The study found that the combined therapy of botulinum toxin and therapeutic exercise had excellent results in a 65-year-old patient, with benefits lasting for more than six months and no side effects. This research provides valuable insights into potential treatment options for individuals with SPS. [Extracted from the article]

A new report from Saint Petersburg State Pediatric Medical University discusses the use of botulinum toxin type A (BTA) for the prevention of hypertrophic and keloid scars after surgeries. The report analyzed 18 prospective randomized studies, which included data on 363 cases. The findings suggest that the use of BTA can reduce the risk of scar formation and the incidence of hypertrophic and keloid scars. However, there is still no consensus on the underlying mechanisms of BTA's positive effect. Further research is needed in this area. [Extracted from the article]

A recent study evaluated the quality of information available on the internet regarding the use of botulinum toxin (botox) for the treatment of bruxism (tooth grinding). The researchers assessed 130 English websites using various tools and found that the information was moderate in quality and difficult to read. They concluded that there is a need for guidelines to improve the quality of websites providing information on botulinum toxin for bruxism treatment. This study highlights the importance of reliable and accessible information on medical treatments available online. [Extracted from the article]

A recent study conducted by Hasanuddin University in Makassar, Indonesia, has found that intradermal botulinum toxin A (BTX-A) monotherapy is an effective treatment for periorbital syringoma, a benign adnexal neoplasm that develops from eccrine sweat ducts. The study focused on a 53-year-old female patient who was successfully treated with BTX-A, which was found to be a painless and cost-effective treatment option that produced better long-term results compared to carbon dioxide laser therapy. This research provides valuable insights into the management of periorbital syringoma and offers a potential solution for individuals seeking cosmetic enhancement in the periorbital region. [Extracted from the article]

A recent study conducted by the University of Verona in Italy has examined the use of botulinum toxin (BoNT) therapy for addressing axial postural abnormalities (APAs) in patients with Parkinson's disease. APAs are characterized by their frequency, disabling nature, and resistance to pharmacological treatments, and they significantly impact the quality of life for individuals with Parkinson's disease. The study found that BoNT treatments, particularly for camptocormia and Pisa syndrome, showed consistent improvements in APAs and pain. However, more research is needed on the combined effects of BoNT and rehabilitation, as well as on antecollis. The study emphasizes the importance of precise injections by skilled clinicians and early rehabilitation in managing APAs, highlighting the need for a multidisciplinary approach. [Extracted from the article]

A recent study from the University of Utah explores the use of botulinum toxin A (BTA) in the treatment of acute burn injuries. The study presents a case report of a 16-year-old male patient with extensive burn injuries who received BTA injections to minimize scarring and reduce contracture formation. The patient did not experience any complications from the injections and was able to actively participate in burn therapy. The study highlights the need for further research on the use of BTA in burn care and the establishment of standardized data collection and benchmarks for range of motion in burn patients. [Extracted from the article]

Researchers from the Peter MacCallum Cancer Centre have published a case report discussing a new finding in botulinum toxin therapy. The report describes a 62-year-old Caucasian female who developed a lytic bone lesion on her forehead after receiving a botulinum toxin injection for cosmetic purposes. The researchers concluded that the injection of the neurotoxin into the underlying bone was the most likely cause of the lesion. This case highlights the need for awareness of this potential complication as the popularity of cosmetic botulinum toxin procedures continues to increase. [Extracted from the article]

A systematic review conducted by researchers at McMaster University in Canada explored the efficacy of botulinum toxin therapy for managing phantom limb pain (PLP) and residual limb pain (RLP) following amputation. The study analyzed 11 articles and found that botulinum toxin injection showed potential for improving PLP and RLP in a significant number of participants. However, due to the limited number of studies, small sample sizes, and variations in methodologies, the researchers concluded that more research is needed to determine the effectiveness of this therapy. This information may be useful for individuals seeking treatment options for chronic pain after amputation. [Extracted from the article]

A recent study conducted at the Centro Hospitalar de Entre o Douro e Vouga provides new insights into the management of nonneurogenic overactive bladder (OAB) in children. OAB is a common voiding dysfunction in children, but nonneurogenic or idiopathic OAB has not been extensively studied. The study explores the use of intravesical botulinum toxin (BoNT) as a treatment option for idiopathic OAB in children, highlighting its efficacy and safety. The results of the study show promising clinical outcomes, with all eight studies reporting good results. The use of BoNT-A is considered a safe and effective treatment for refractory idiopathic OAB in pediatric settings. This is the first systematic review of the use of intravesical BoNT-A for idiopathic OAB treatment in children. [Extracted from the article]

A recent study conducted at Queen Elizabeth II Jubilee Hospital examined the use of botulinum toxin therapy as a treatment for dyssynergic defaecation (DD), a common cause of chronic constipation. The study found that injections of botulinum toxin A (BTX-A) into the puborectalis and anal sphincter muscles can be effective in improving symptoms in the short term. The procedure was generally safe, with rare and mild complications reported. However, the study also found that the efficacy of BTX-A injections was limited to the short term, with only two cases showing sustained improvement beyond 12 months. Overall, the study suggests that BTX-A injections can be a safe treatment option for DD, but their long-term effectiveness is limited. [Extracted from the article]

A recent study conducted by researchers at Universite Paris Cite explores the effects of botulinum toxin A (BoNT/A) on neuropathic pain. The study reveals that BoNT/A, which is commonly used to treat neurological disorders, not only affects the peripheral nervous system but also has an impact on the central nervous system (CNS). The researchers suggest that BoNT/A may modulate synaptic function and interfere with the activity of spinal, brain stem, and cortical circuitry, potentially offering a new approach to managing chronic neuropathic pain. The study provides a systematic review of the mechanisms and effects of BoNT/A on peripheral and central neuroplasticity. [Extracted from the article]

A report from Xinjiang Medical University in Urumqi, China, discusses the effect and mechanism of action of botulinum toxin type A (BTXA) on hypertrophic scars. The study found that BTXA suppressed the MAPK pathway in hypertrophic scar fibroblasts, leading to a reduction in collagen deposits and inhibited growth and motility of scar cells. The researchers concluded that BTXA has the potential to be developed as a drug for the treatment of hypertrophic scarring. This research was supported by the Xinjiang Uygur Autonomous Region Natural Science Foundation Youth Fund of China. [Extracted from the article]

A new report discusses the research findings on botulinum toxin therapy. The report highlights the evolution of botulinum toxin from a potent neurotoxin to a commonly used treatment in clinical practice. The research explores the potential benefits of botulinum toxin for conditions related to cholinergic transmission, such as autonomic nervous system dysfunction. The report provides an overview of the effect of botulinum toxin in treating autonomic dysfunction, including different formulations, dosages, outcomes, and adverse events. The research aims to fill the gap in comprehensive reviews on the therapeutic use of botulinum toxin for autonomic dysfunction. [Extracted from the article]

A study conducted at Children's Mercy Hospitals in Kansas City, Missouri, explored the use of botulinum toxin therapy as a treatment for refractory vulvodynia in adolescents. Vulvodynia is a condition characterized by vulvar discomfort without an identifiable cause. The study found that transvaginal botulinum toxin injections into the pelvic floor were effective in treating vulvodynia in select adolescent patients who had not responded well to other interventions. However, further research is needed to determine the optimal dosing, frequency, and sites of botulinum toxin injections for pediatric and adolescent patients with vulvodynia. This research was supported by the NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development. [Extracted from the article]

A study conducted at the Shanghai Skin Disease Hospital in China investigated the therapeutic effects of botulinum toxin type A (BTX-A) on hypertrophic scar (HS) tissue in mice. HS is a disorder characterized by the excessive proliferation of fibrous tissue during wound healing, causing pain, itching, and ulceration. The study found that BTX-A inhibited the formation of HS by regulating apoptosis, reducing the formation of myofibroblasts and collagen deposition, and improving the arrangement of collagen fibers. The researchers concluded that BTX-A could be an effective treatment for HS. [Extracted from the article]

A study conducted in Timisoara, Romania, examined the effectiveness of botulinum toxin (Botox) therapy in reducing sweat production and improving the quality of life in patients with axillary hyperhidrosis. The study involved 81 patients and found that sweat production decreased significantly over one year of treatment, from 0.81 g to 0.23 g per 15 minutes. The severity of symptoms also decreased, as indicated by a reduction in Hyperhidrosis Disease Severity Scale (HDSS) scores. Quality of life, particularly in social and environmental aspects, showed significant improvements. The study suggests that Botox therapy may have long-term benefits for hyperhidrosis patients. [Extracted from the article]

Researchers from Sapienza University of Rome have conducted a study on the use of botulinum toxin type A (BTX-A) in dentistry for aesthetic purposes. The study analyzed the regulatory measures on BTX-A administration in all European Union (EU) member states and found a varied regulatory framework, highlighting the need for convergence measures between legislations. The researchers argue that harmonizing dental competences is important not only for professionals' mobility within the EU but also to ensure patient health and prevent market distortions. The study emphasizes the importance of common competences and regulatory measures in the field of aesthetic medicine in dentistry. [Extracted from the article]

A study conducted in Andhra Pradesh, India, explored the use of botulinum toxin type A (BTX-A) in treating spasticity in children with cerebral palsy (CP). The study compared the outcomes of immediate versus delayed casting as an adjunct to BTX-A therapy for spasticity in lower limb muscles. The research found that delaying casting after BTX-A injection resulted in better clinical and functional outcomes, as measured by the Edinburgh visual gait score. This study suggests that there is a clear benefit in delaying casting after BTX-A injection to reduce the recurrence of spasticity in children with CP. [Extracted from the article]

A recent study conducted in Szczecin, Poland, has found that botulinum toxin therapy is an effective treatment for overactive bladder (OAB) in female patients. The study aimed to compare the quality of life of patients with OAB before and after botulinum toxin treatment. The results showed that three and six months after the intervention, the scores for three validated questionnaires assessing quality of life were significantly lower than before treatment, indicating a reduction in OAB symptoms and their impact on quality of life. However, the severity of symptoms and their impact on quality of life were higher at six months compared to three months post-intervention. Overall, the study concludes that botulinum toxin therapy is an effective treatment for OAB. [Extracted from the article]

A recent study conducted at the University of Rosario compared the efficacy of Botulinum Toxin (BT) type B versus type A and placebo in patients with cervical dystonia (CD). The study found that BT type B was effective in improving TWSTRS scores at 4 weeks compared to placebo. However, there was no significant difference in efficacy between BT type B and type A. Adverse events such as dry mouth and dysphagia were more frequent in the BT type B group. The researchers concluded that further studies are needed to evaluate therapeutic options for patients resistant to BT type A. [Extracted from the article]

This patent application discusses the need for non-protein excipients to stabilize Clostridial toxins in pharmaceutical compositions. The application proposes various non-protein excipients, such as tonicity agents, surfactants, antioxidants, and lyoprotectants, to stabilize Clostridial toxins. The compositions can be in liquid or solid form and may include ingredients like trehalose, sodium chloride, poloxamer, polysorbate, and buffering agents. The goal is to develop safe and effective pharmaceutical compositions for Clostridial toxin therapy. The patent application describes various embodiments of non-protein compositions containing Clostridial toxins, specifically botulinum toxin, for use in pharmaceutical formulations. The compositions exclude albumin and may include ingredients such as poloxamer, methionine, disaccharides, surfactants, antioxidants, chelating agents, and chain terminators. The patent application also includes methods for making stable solid and liquid pharmaceutical compositions and their potential use in treating depression and cardiac arrhythmia. The compositions are designed to be suitable for subcutaneous or intramuscular injection. [Extracted from the article]